Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
©2013 UpToDate ® Print Email Calculated risk of natalizumab-related PML according to currently known risk factors Prior chemotherapy? Overall risk Risk up to 24 mo therapy Risk after 24 mo therapy JC virus antibody negative No ∼1:17,693 ∼1:51,526 ∼1:9629 Yes ∼1:6239 ∼1:18,171 ∼1:3396 JC virus antibody positive No ∼1:442 ∼1:1288 ∼1:241 Yes ∼1:177 ∼1:454 ∼1:85 PML: progressive multifocal leukoencephalopathy. Reproduced with permission from: Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436. Copyright © 2012 Lippincott Williams & Wilkins.